Hubbry Logo
HeminHeminMain
Open search
Hemin
Community hub
Hemin
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Hemin
Hemin
Hemin
View on Wikipedia
from Wikipedia

Hemin
Clinical data
AHFS/Drugs.comConsumer Drug Information
Routes of
administration		Intravenous infusion
ATC code
Legal status
Legal status
Identifiers
  • Chloro[3,7,12,17-tetramethyl-8,13-divinylporphyrin-2,18-dipropanoato(2−)]iron(III)
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.036.475 Edit this at Wikidata
Chemical and physical data
FormulaC34H32ClFeN4O4
Molar mass651.95 g·mol−1
3D model (JSmol)
  • OC(=O)CCC=5C1=C\C6=N\C(=C/c3n2[Fe](Cl)N1C(=C\C4=N\C(=C/c2c(C=C)c3C)C(/C)=C4/C=C)/C=5C)C(\C)=C6\CCC(O)=O
  • InChI=1S/C34H34N4O4.ClH.Fe/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;/h7-8,13-16H,1-2,9-12H2,3-6H3,(H4,35,36,37,38,39,40,41,42);1H;/q;;+3/p-3/b25-13-,26-13-,27-14-,28-15-,29-14-,30-15-,31-16-,32-16?;; checkY
  • Key:BTIJJDXEELBZFS-UKFHATERSA-K checkY
 ☒NcheckY (what is this?)  (verify)

Hemin (haemin; ferric chloride heme) is an iron-containing porphyrin with chlorine that can be formed from a heme group, such as heme B found in the hemoglobin of human blood.

Chemistry

[edit]

Hemin is protoporphyrin IX containing a ferric iron (Fe3+) ion with a coordinating chloride ligand.

Hemin is a dark brown solid that is almost insoluble in water, but soluble in alkaline aqueous solutions to form a dark green aqueous solution of hematin.

Chemically, hemin differs from the related heme-compound hematin chiefly in that the coordinating ion is a chloride ion in hemin, whereas the coordinating ion is a hydroxide ion in hematin.[2] The iron ion in haem is ferrous (Fe2+), whereas it is ferric (Fe3+) in both hemin and hematin.

Hemin is endogenously produced in the human body, for example during the turnover of old red blood cells. It can form inappropriately as a result of hemolysis or vascular injury. Several proteins in human blood bind to hemin, such as hemopexin and serum albumin.

Hemin reacts with hydrogen cyanide in ammonia solution to form a blood-red complex.

The color change of hemin in ammonia solution upon contact with hydrogen cyanide. Left: hemin in ammonia solution, dark green to blackish brown; Right: After reacting with hydrogen cyanide, it turns blood red.

Pharmacological use

[edit]

A lyophilised form of hemin is used as a pharmacological agent in certain cases for the treatment of porphyria attacks, particularly in acute intermittent porphyria. Administration of hemin can reduce heme deficits in such patients, thereby suppressing the activity of delta-amino-levulinic acid synthase (a key enzyme in the synthesis of the porphyrins) by biochemical feedback, which in turn reduces the production of porphyrins and of the toxic precursors of heme. In such pharmacological contexts, hemin is typically formulated with human albumin prior to administration by a medical professional, to reduce the risk of phlebitis and to stabilize the compound, which is potentially reactive if allowed to circulate in free-form. Such pharmacological forms of hemin are sold under a range of trade names including the trademarks Panhematin[3] and Normosang.[4]

History of isolation

[edit]

Hemin was first crystallized out of blood in 1853, by Ludwik Karol Teichmann. Teichmann discovered that blood pigments can form microscopic crystals. Thus, crystals of hemin are occasionally referred to as 'Teichmann crystals'. Hans Fischer synthesized hemin, for which he was awarded the Nobel Prize in Chemistry in 1930.[5] Fischer's procedure involves treating defibrinated blood with a solution of sodium chloride in acetic acid.[6]

Forensics

[edit]

Hemin can be produced from hemoglobin by the so-called Teichmann test, when hemoglobin is heated with glacial acetic acid (saturated with saline). This can be used to detect blood traces.

Other

[edit]

Hemin is considered the "X factor" required for the growth of Haemophilus influenzae.[7]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Hemin

View on Grokipedia
from Grokipedia
Hemin is an iron-containing compound, specifically ferriprotoporphyrin IX , that serves as a pharmaceutical preparation of derived from processed cells, primarily used to treat acute attacks of by replenishing the pool and inhibiting excessive production. Chemically, hemin consists of —a ring with a central ferric iron atom coordinated to a —making it a stable, water-soluble form suitable for intravenous administration under the brand name Panhematin. It is prepared by extracting from outdated cells, treating it with to form the chloride complex, and lyophilizing it for reconstitution. This structure allows hemin to mimic natural , the in and other hemoproteins, while providing a therapeutic intervention for disorders of heme biosynthesis. In clinical practice, hemin is indicated for the management of recurrent attacks of (AIP), hereditary coproporphyria, and , particularly in women when attacks are associated with the and therapy has failed. It works by repressing the activity of delta-aminolevulinic acid synthase (ALAS1), the rate-limiting enzyme in synthesis, thereby reducing the accumulation of toxic precursors that cause neurological and abdominal symptoms during acute episodes. Administered intravenously over at least 30 minutes, typically at doses of 1–4 mg/kg daily for 3–4 days, hemin requires careful monitoring for side effects such as , , or due to its iron content. Beyond porphyria, preclinical research explores hemin's potential in inflammatory conditions through induction of heme oxygenase-1 (HO-1), which exerts and effects, though these applications remain investigational.

Chemical Properties

Structure and Composition

Hemin is the chloride salt of ferric heme, specifically iron(III) protoporphyrin IX, in which the central iron atom exists in the +3 oxidation state and is axially coordinated by a chloride ligand. This compound serves as a key derivative in biochemical and pharmaceutical contexts, distinguishing it from its ferrous counterpart. In comparison, heme refers to the iron(II) protoporphyrin IX complex with Fe²⁺ and no chloride ligand, while hematin is the ferric form featuring a hydroxide (OH⁻) ligand instead of chloride; protoheme is synonymous with heme. The chemical formula of hemin is \ceC34H32ClFeN4O4\ce{C34H32ClFeN4O4}, with a molecular weight of approximately 651.95 g/mol. At its core, hemin features a macrocycle, a ring system composed of four subunits interconnected by methine bridges (=\ceCH−=\ce{CH}-), and bearing two vinyl side chains, four methyl groups, and two side chains. This substitution pattern on the porphyrin scaffold provides the specific reactivity and coordination properties essential to hemin's function. Hemin forms via the oxidation of , which shifts the iron from the Fe²⁺ to Fe³⁺ state, enabling subsequent coordination of the to the ferric center under appropriate conditions.

Physical and Spectroscopic Characteristics

Hemin appears as a dark to black crystalline powder. It exhibits limited in , remaining practically insoluble under neutral conditions, but dissolves readily in alkaline solutions such as dilute or , where it may form the related hematin species; it is also soluble in (DMSO) and , while being insoluble in . Hemin demonstrates sensitivity to light exposure and reducing agents, which can promote its degradation, and in aqueous solutions, it tends to decompose into hematin, the μ-oxo dimer form. In ultraviolet-visible (UV-Vis) , hemin displays characteristic absorption maxima, including a prominent Soret band at approximately 385 nm and Q bands in the 540-570 nm range, with these features varying slightly depending on and aggregation state. Fourier-transform infrared (FTIR) reveals a key band for the Fe(III)-Cl stretch at around 345 cm⁻¹, confirming the axial ligation in the ferric structure. Due to the paramagnetic nature of the high-spin Fe(III) center, ¹H (NMR) of shows strongly shifted signals for protons, with methyl groups appearing downfield at 70-85 ppm and meso protons exhibiting upfield shifts near -20 to 0 ppm, providing insights into the electronic environment around the metal. The aggregation behavior of hemin is highly pH-dependent, forming oligomeric or aggregated species at neutral pH that exhibit broadened UV-Vis spectra, whereas in basic conditions (pH > 8), it predominantly exists as monomers with sharper, red-shifted absorption bands.

Biological Aspects

Biosynthesis and Endogenous Formation

Heme biosynthesis is a conserved eight-step enzymatic pathway that occurs primarily in mammals to produce heme, the iron-containing prosthetic group essential for hemoproteins such as hemoglobin and cytochromes. The pathway begins in the mitochondria with the rate-limiting step catalyzed by δ-aminolevulinic acid (ALA) synthase (ALAS), which condenses and to form ALA. This is followed by cytosolic steps: ALA dehydratase converts two ALA molecules to porphobilinogen (PBG), PBG deaminase assembles four PBG units into hydroxymethylbilane, and uroporphyrinogen III synthase cyclizes it to uroporphyrinogen III. Subsequent decarboxylation by uroporphyrinogen decarboxylase yields coproporphyrinogen III, which re-enters the mitochondria where coproporphyrinogen oxidase and protoporphyrinogen oxidase sequentially oxidize it to . The final mitochondrial step involves ferrochelatase inserting Fe²⁺ into to form . The pathway is compartmentalized, with the initial and terminal steps (1, 6–8) in mitochondria and intermediate steps (2–5) in the cytosol, requiring transport of intermediates across membranes. Key regulatory enzyme ALAS exists in two isoforms: ALAS1 (ubiquitous, including hepatocytes) and ALAS2 (erythroid-specific). Heme synthesis occurs mainly in erythroid precursor cells of the bone marrow, accounting for approximately 80–85% of total body heme production for hemoglobin, and in hepatocytes of the liver for cytochromes and other hemoproteins. Regulation is achieved through feedback inhibition by heme on ALAS1, which represses its transcription, destabilizes mRNA, and inhibits mitochondrial import, thereby preventing overproduction; the oxidized form, hemin, similarly downregulates ALAS1 activity. Hemin, the ferric (Fe³⁺) form of , forms endogenously through oxidation of (Fe²⁺) released during turnover or . In physiological RBC turnover, senescent cells are phagocytosed by macrophages, where is liberated from and rapidly oxidized to hemin non-enzymatically by (ROS) or plasma oxidants like . During pathological , oxidizes to (Fe³⁺), facilitating hemin release, which can occur spontaneously or be accelerated by and ROS. Heme oxygenase-1 (HO-1), induced in response to free , then binds hemin, reduces it to ferrous for degradation into , , and iron, but the initial oxidation step precedes this enzymatic process. Disruptions in , such as deficiencies in porphyrias (e.g., due to porphobilinogen deaminase deficiency or from ferrochelatase defects), lead to accumulation of precursors and overall deficits in and hemin production, contributing to clinical manifestations like neurological symptoms or .

Metabolism and Transport

Heme degradation in mammals is primarily initiated by the enzymes heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2), which catalyze the oxidative cleavage of the porphyrin ring to produce , (CO), and free ferrous iron (Fe²⁺). This process requires NADPH and molecular oxygen, with electrons supplied by , and serves as the main pathway for eliminating potentially toxic free derived from hemoproteins like . Subsequently, is rapidly reduced to by biliverdin reductase (BVR), a cytosolic that uses NADPH as a cofactor, completing the initial catabolic steps. To prevent cellular damage from free heme or hemin, specialized plasma proteins facilitate its and sequestration. Hemopexin (Hx) binds free with high affinity (dissociation constant ~10⁻¹³ M), forming a stable complex that delivers heme to hepatocytes for degradation via . serves as a lower-affinity carrier (dissociation constant ~10⁻⁷ M), temporarily binding excess heme when hemopexin is saturated, while primarily complexes with to limit heme release from intact erythrocytes. These proteins collectively maintain low circulating levels of unbound heme, mitigating its pro-oxidant potential. Iron liberated from degraded heme is efficiently recycled to support , primarily through macrophages that phagocytose senescent erythrocytes, accounting for 80-90% of daily heme turnover (approximately 20-25 mg of iron). The released iron is exported from macrophages via , the sole known iron exporter, which is regulated by to balance systemic iron homeostasis. Meanwhile, —the end product of heme —is transported to the liver, where it undergoes conjugation with by UDP-glucuronosyltransferase 1A1 (UGT1A1) to form water-soluble bilirubin diglucuronide, which is then actively secreted into via the canalicular for fecal . In pathological conditions such as hemolysis, elevated free hemin levels overwhelm transport and degradation systems, leading to oxidative stress through Fenton chemistry. Here, ferric iron (Fe³⁺) in hemin is reduced to ferrous iron (Fe²⁺), which reacts with hydrogen peroxide to generate highly reactive hydroxyl radicals (•OH), damaging lipids, proteins, and DNA in vascular and tissue compartments. This mechanism contributes to endothelial dysfunction and inflammation in hemolytic disorders like sickle cell disease.

Medical Applications

Treatment of Acute Porphyrias

Hemin, administered intravenously, serves as the cornerstone therapy for managing acute attacks of hepatic porphyrias, including (AIP), , and hereditary coproporphyria, by addressing the underlying deficiency that exacerbates these conditions. These disorders arise from partial deficiencies in hepatic biosynthetic enzymes, leading to accumulation of neurotoxic precursors such as delta-aminolevulinic acid (ALA) and porphobilinogen (PBG). The treatment replenishes depleted pools in the liver, thereby restoring feedback regulation in the biosynthetic pathway. The primary mechanism of hemin involves repression of the rate-limiting enzyme ALA synthase 1 (ALAS1), which reduces the overproduction of ALA and PBG, the porphyrin precursors responsible for the neurovisceral symptoms of acute attacks. This inhibition occurs through on ALAS1 transcription and activity, as directly modulates the enzyme's expression and stability. By alleviating the buildup of these toxic intermediates, hemin mitigates the , , and psychiatric manifestations characteristic of these porphyrias. Administration of hemin typically involves intravenous infusion of 3-4 mg/kg body weight daily for 3-4 days, with dosing adjusted based on clinical response and extending up to 14 days in severe cases. In the United States, the standard formulation is Panhematin, a lyophilized preparation of hemin complexed with human to enhance stability, while in , Normosang (heme arginate) is commonly used as an alternative arginine-stabilized form. To minimize risks such as , the drug is diluted in normal saline or solution and infused over at least 30 minutes via a large , often with a central line in prolonged therapy. Clinical efficacy is evidenced by rapid symptom resolution, with reductions in and neuropathy often occurring within 24-48 hours of initiation, alongside normalization of urinary ALA and PBG levels in most patients. Early administration during an attack enhances outcomes, preventing progression to severe complications like respiratory , and is endorsed as the first-line intervention by guidelines from the American Porphyria Foundation. Studies confirm that hemin is more potent than supportive measures like glucose loading in suppressing precursor accumulation, leading to complete remission in the majority of treated episodes. Potential side effects include , due to hemin's procoagulant properties, as well as from repeated dosing and transient manifested as decreased clotting factors. at the infusion site is common but can be mitigated by proper dilution and vein selection. Monitoring involves serial assessment of levels to detect iron accumulation and parameters to manage thrombotic risks, with discontinuation if severe adverse events arise. Hemin , as Panhematin, received FDA approval on July 20, 1983, specifically for the amelioration of recurrent attacks in AIP, marking it as the first targeted pharmacologic intervention for these life-threatening disorders.

Emerging Therapeutic Roles

Hemin has garnered attention for its potential anti-inflammatory effects through the induction of heme oxygenase-1 (HO-1), which mitigates in various pathological conditions. In models of , hemin-mediated HO-1 upregulation protects against lipopolysaccharide-induced by reducing pro-inflammatory release and tissue . Similarly, in ischemia-reperfusion , such as in cardiac or intestinal models, hemin pretreatment enhances HO-1 expression, preserving organ function and decreasing markers of like . For neurodegenerative diseases, including Alzheimer's, hemin-induced HO-1 activation counters amyloid-β toxicity by generating , which inhibits and neuronal , while elevated serum HO-1 levels correlate with disease progression but suggest therapeutic modulation potential. Beyond , hemin exhibits properties primarily by sequestering iron essential for and generating (ROS) that disrupt microbial membranes. Studies demonstrate hemin's inhibitory effects on , where it impairs bacterial proliferation through thiol-dependent mechanisms and DNA damage, outperforming certain metal protoporphyrin complexes in antibacterial potency. This iron-withholding action limits pathogen , as seen in heme-dependent siderophore utilization pathways disrupted under hemin-limited conditions. In wound care applications, hemin-incorporated nanocomposites, such as silver-decorated lysozyme-hemin in hydrogels, enhance bactericidal activity against wound pathogens while promoting healing, offering a promising antibiotic-free alternative for chronic wounds. In cancer research, hemin's pro-oxidant effects leverage ROS generation to induce apoptosis selectively in tumor cells. Exposure to hemin triggers intracellular ROS accumulation, leading to DNA damage and enhanced HO-1 activity that tips the balance toward cell death in malignant lines, such as colon cancer cells, without equivalent harm to non-malignant counterparts. This dual role—antioxidant at low doses via HO-1 but pro-apoptotic at higher concentrations via ferrous iron-mediated ROS—positions hemin as a candidate for targeted therapies, particularly in heme-sensitive tumors like breast cancer where it amplifies cytotoxicity. Recent investigations (2020–2025) explore hemin's therapeutic potential in clinical contexts beyond porphyrias, though progress remains preclinical or early-stage. In , hemin-binding compounds show promise in reducing activation and vaso-occlusive pain crises in murine models by mitigating hemin release from , with ongoing preclinical data supporting anti-inflammatory benefits in lung and kidney complications. For in , hemin induces transient via DNA damage response in models, conferring protection against , while rat ischemia studies demonstrate reduced infarct volume through HO-1-mediated pathways. No phase II trials for hemin in these indications were identified as of 2025, highlighting the need for further human studies. Despite these prospects, hemin's translation to broader therapeutics faces challenges related to dosing, toxicity, and delivery. High doses risk iron overload and pro-oxidant toxicity, exacerbating cellular damage in sensitive tissues like the brain, while intravenous administration limits accessibility and requires careful timing to avoid aggregation issues. Knowledge gaps in pharmacokinetics for repurposing, such as optimal non-porphyria dosing (typically 1–4 mg/kg/day IV), underscore regulatory hurdles, with practical concerns including infusion stability and potential for hemolytic exacerbation in vulnerable patients.

Historical Development

Early Isolation and Discovery

The early isolation of hemin emerged within the broader 19th-century advancements in , where scientists began linking blood pigments to iron-containing compounds essential for oxygen transport. Researchers like and had earlier explored blood's chemical composition, but systematic studies intensified in the mid-1800s, focusing on the red pigment and its derivatives. This period saw the recognition that blood's coloration stemmed from iron-bound molecules, laying groundwork for isolating crystalline forms of these pigments. A pivotal breakthrough occurred in 1853 when Polish anatomist Ludwik Karol Teichmann successfully crystallized from human blood by treating dried blood samples with glacial acetic acid and , forming rhomboid or diamond-shaped microscopic crystals known as Teichmann crystals. These crystals represented the chloride derivative of , providing the first visual confirmation of blood pigment's crystalline nature and serving as a precursor to the Teichmann test for blood identification. Teichmann detailed this method in his seminal paper published in the Zeitschrift für rationelle Medizin, emphasizing the crystals' diagnostic potential in distinguishing blood from other substances. Building on this, German physiologist Felix Hoppe-Seyler advanced the understanding of hematin—the oxidized form related to hemin—in the 1860s and 1870s through spectroscopic analyses and isolation techniques from and pigments. Hoppe-Seyler isolated hematin crystals and described their spectral properties, contributing to the differentiation of pigments and the coining of terms like "hematoporphyrin" for the iron-free derivative obtained by acid treatment. His work, published in Medizinisch-chemische Untersuchungen, solidified hematin's role as a key iron-containing component. In 1871, German physiologist Gustav Preyer further confirmed the iron content in these crystals through quantitative analyses in his Die Blutkrystalle, where he examined hemin-like crystals from various animal and quantified their iron composition using chemical assays. Preyer's and crystallographic studies reinforced that iron was integral to the pigment's structure, bridging microscopic observations with . By the late 1800s, these isolations found initial practical use in , where Teichmann's crystal test enabled the presumptive detection of traces at scenes, aiding early criminal investigations despite limitations in sensitivity.

Synthesis and Pharmaceutical Advancements

The of was first achieved in the 1920s by German chemist , who constructed the porphyrin ring through the condensation of four units, followed by metalation with iron to form . Fischer's approach involved the stepwise assembly of α-substituted , enabling the precise positioning of methyl, vinyl, and side chains characteristic of , the core structure of . Hemin, the ferric chloride complex of , was subsequently derived by oxidation to the Fe³⁺ state and coordination with chloride ions. For this groundbreaking work on the structure and synthesis of blood pigments, including haemin (an early term for hemin), Fischer was awarded the in 1930. Pharmaceutical production of hemin traditionally relies on extraction from outdated human red blood cells due to regulatory requirements for therapeutic use and high heme content. The process begins with the isolation of red blood cells from processed blood, followed by lysis to release hemoglobin, acidification to dissociate heme from globin, and purification through solvent extraction and crystallization. This method yields hemin as dark crystals, suitable for pharmaceutical-grade material after rigorous testing for purity. In recent years, recombinant techniques have emerged as alternatives, engineering yeast (such as Pichia pastoris or Saccharomyces cerevisiae) or bacteria (like Escherichia coli or Corynebacterium glutamicum) to overexpress the heme biosynthetic pathway, achieving heme titers up to several milligrams per liter through metabolic engineering and cofactor optimization. These microbial approaches mitigate reliance on human-derived materials and enable scalable, contaminant-free production. Key challenges in hemin production include contamination risks from biological sources and optimizing yields during purification. Human blood extractions carry potential for viral or bacterial contaminants, necessitating stringent sourcing, viral inactivation steps, and quality controls to ensure safety for therapeutic use. Yield optimization often involves in hot glacial acetic acid saturated with , which promotes the formation of pure hemin crystals while minimizing impurities, though large-scale operations require careful control of and to avoid aggregation or . Pharmaceutical advancements began in the with the development of hematin for intravenous use, culminating in the FDA approval of Panhematin (hemin for injection) in 1983 as the first commercial product for treating acute s. In 2017, Recordati Rare Diseases introduced a new 350 mg single-vial dosage strength of Panhematin, featuring an updated with enhanced stability to reduce degradation during storage and reconstitution. Post-1930 developments focused on scaling up production for clinical applications, particularly in the , when optimized extraction and lyophilization processes enabled reliable supply for use, supporting broader adoption in porphyria management.

Forensic Applications

Detection Methods for Blood Traces

The Teichmann test, also known as the hemin or hematin test, is a classic microcrystalline confirmatory method for detecting blood traces in forensic samples by forming characteristic crystals from . In this procedure, a small portion of the suspected bloodstained material, such as a scraping or cutting from fabric or a surface, is placed on a clean . A drop of glacial acetic acid is added, followed by a few crystals of (NaCl), and the slide is covered with a coverslip. The preparation is then gently heated on a or in a water bath at approximately 25–62.5°C until the acetic acid evaporates, after which it cools to . Under a at 100× to 400× magnification, the presence of blood is confirmed by the formation of brown, rhomboid or diamond-shaped hematin chloride (hemin) crystals, often appearing singly, in clusters, or in sheaves; these crystals may also exhibit bubbling when exposed to due to residual activity. This test exhibits high specificity for human or mammalian , as the hemin crystals derive from the iron in , distinguishing it from non-heme substances. It can detect minute quantities of , making it suitable for analysis. However, limitations include false negatives from old, washed, or chemically treated stains, as well as interference from excessive heat (above 140–145°C) that degrades ; while generally free of false positives, rare cases involving strong plant peroxidases have been noted to potentially mimic crystal formation, though confirmatory mitigates this. An alternative crystal-based method is the Takayama test, which forms hemochromogen crystals rather than hemin, offering complementary confirmation for blood traces. The protocol involves preparing a reagent mixture of saturated glucose solution, 10% , , and in a 1:1:1:2 ratio; a small amount of the is scrubbed onto a slide, 2–3 drops of are added, and a coverslip is applied before microscopic observation, with gentle warming if crystals do not appear within 6 minutes. Pink or red feathery or needle-like crystals in clusters confirm the presence of heme-derived ferroprotoporphyrin, visible at similar magnifications to the Teichmann test. This method is particularly useful for older stains, maintaining detectability after 30 days of submersion in freshwater, though it is less sensitive than presumptive tests and may require up to 30 minutes for results, with no crystal formation indicating a negative outcome. Modern spectroscopic approaches, such as , provide nondestructive alternatives by identifying the unique vibrational signature of hemin's ring in traces. Using near-infrared excitation, Raman spectra of dried exhibit characteristic peaks from the group, including strong signals at 753 cm⁻¹ (pyrrole ring deformation), 1372 cm⁻¹ ( skeletal mode), and 1577 cm⁻¹ ( ring modes), allowing detection on various substrates without sample destruction. This technique is highly specific for , even in the presence of contaminants, and supports trace analysis at picogram levels, though it requires specialized equipment and may be affected by from degraded samples.

Role in Criminal Investigations

The hemin crystal test, known as the Teichmann test, has long served as a confirmatory method for detecting in criminal investigations, offering evidentiary value in establishing the presence of at crime scenes for and cases since the . Developed in 1853 by Ludwig Teichmann, the test produces distinctive rhomboid hemin crystals from derivatives when treated with glacial acetic acid and salts, providing a specific indicator of that has been admissible in courts as supporting of violent crimes. In the , the test featured prominently in the trial for the murder of Ora Lee in , where forensic chemist John Spenzer employed it alongside spectroscopic as part of the first expert testimony on testing in a U.S. , aiding in the examination of stains on clothing and vehicles. Modern protocols integrate hemin tests with DNA by allocating a minimal portion of the stain for crystal preparation, thereby preserving sufficient material for subsequent PCR-based profiling to link evidence to suspects or victims. Although immunochemical assays like RSID-Blood have shifted primary confirmatory roles due to their rapidity and specificity, the hemin test persists as a presumptive screening tool, especially in resource-limited settings where its low cost—requiring only basic chemicals and a —facilitates accessible detection without advanced instrumentation. Challenges to its application include the subjective evaluation of crystal shapes via , which has prompted admissibility challenges in trials due to potential interpretive variability. ASTM International addresses such issues through standards guiding the forensic examination of biological evidence, ensuring procedural consistency and enhancing the test's reliability in legal proceedings.

Other Uses and Recent Research

Applications in Microbiology

Hemin serves as , a critical growth requirement for fastidious such as , which cannot synthesize and thus depend on exogenous derivatives to form essential involved in aerobic respiration. These , including certain Haemophilus species and other heme auxotrophs, utilize hemin to incorporate iron and into their respiratory chain enzymes, enabling electron transport and ATP production. Without hemin supplementation, growth is severely impaired, highlighting its role in supporting the metabolic needs of these pathogens in nutrient-limited environments. In microbiological media preparation, hemin is commonly provided through , where is heated to 80–85°C, lysing erythrocytes and releasing intracellular NAD (V factor) while solubilizing hemin from for accessibility. This enriched medium supports the cultivation of H. influenzae and related species that require both X and V factors, as the heating process denatures inhibitory proteins and makes the factors bioavailable without degradation. The resulting chocolate-like appearance of the reflects the incorporation of lysed components, facilitating robust formation for isolation and identification. Diagnostically, hemin-enriched media like chocolate agar are employed in culturing throat swabs to detect Haemophilus species from upper respiratory infections, where growth patterns confirm the presence of these bacteria. This approach distinguishes Haemophilus from Neisseria species, as the latter typically require only the X factor and can grow on standard blood agar, whereas Haemophilus exhibits satellite growth around streptococcal colonies on blood agar due to NAD diffusion or fails to grow without chocolate agar supplementation. Such tests are integral to routine clinical microbiology for identifying respiratory pathogens. Synthetic hemin supplements, such as hemin chloride, offer alternatives to blood-derived sources in defined culture media, ensuring consistent availability of the X factor for reproducible bacterial growth without variability from biological extracts. These purified compounds are added at concentrations of 5–10 µg/mL to basal media for cultivating heme-dependent anaerobes and facultative pathogens, reducing contamination risks and supporting quantitative assays. Their use enhances precision in research and diagnostic settings, particularly for fastidious organisms like Bacteroides and Haemophilus.

Industrial and Environmental Applications

Hemin serves as a key component in mimetics, particularly in composites like hemin-graphene hybrids that exhibit peroxidase-like for the degradation of organic dyes through activation of . Similarly, hemin-TiO₂ composites enable efficient under visible light, breaking down pollutants like with enhanced efficiency compared to pure TiO₂, achieving up to 96% degradation. In , hemin-functionalized electrodes facilitate the electrochemical reduction of carcinogenic nitrosamines, such as N-nitrosodimethylamine, in secondary effluents from treatment plants, converting them to less harmful hydrazines via proton-mediated pathways. These systems demonstrate practical for removing trace contaminants in industrial effluents without additional chemical additives. Additionally, hemin-based photocatalysts support visible-light-driven degradation of various organic pollutants, promoting sustainable remediation processes. Hemin-peptoid hybrids form stable nanozyme structures that exhibit peroxidase-like activity for applications such as in production. These hybrids leverage hemin's catalytic properties and offer superior stability in harsh conditions, maintaining activity across 3–10 and temperatures up to 60°C, which reduces operational costs and waste in industrial applications. This robustness stems from hemin's structure, which supports tunable peroxidase-like mechanisms without denaturation. Recent advancements from 2020 to 2025 include Z/Ce@hemin composites, which enhance activity for sensitive detection of pollutants like in models, adaptable for environmental sensing with limits of detection below 1 μM. These developments align with the broader growth in markets, projected to expand at 10.84% annually through 2030, driven by demand for sustainable catalysts in control and production.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11048114/
  2. https://go.drugbank.com/drugs/DB03404
  3. https://www.mayoclinic.org/drugs-supplements/hemin-intravenous-route/description/drg-20406498
  4. https://pubchem.ncbi.nlm.nih.gov/compound/Hemin
  5. https://www.sciencedirect.com/topics/neuroscience/hematin
  6. https://www.chemspider.com/Chemical-Structure.401223.html
  7. https://hmdb.ca/metabolites/HMDB0000241
  8. https://pubchem.ncbi.nlm.nih.gov/compound/protoporphyrin-IX
  9. https://www.ahajournals.org/doi/10.1161/JAHA.114.001138
  10. https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/documents/325/626/h2250pis.pdf
  11. https://pmc.ncbi.nlm.nih.gov/articles/PMC10343206/
  12. https://pubmed.ncbi.nlm.nih.gov/15907864/
  13. https://www.sciencedirect.com/science/article/abs/pii/S0924203108000386
  14. https://pubs.acs.org/doi/10.1021/ja00514a036
  15. https://www.cambridge.org/core/journals/quarterly-reviews-of-biophysics/article/ferric-heme-b-in-aqueous-micellar-and-vesicular-systems-stateoftheart-and-challenges/CD7446B98C42EE29547FB8DDEF236D25
  16. https://www.ncbi.nlm.nih.gov/books/NBK537329/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC2895239/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC3136693/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC7252266/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC4485156/
  21. https://ashpublications.org/blood/article/121/8/1276/138819/Hemolysis-and-free-hemoglobin-revisited-exploring
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC3961788/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC7766613/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4207996/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4211382/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC2913068/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC4635047/
  28. https://www.ncbi.nlm.nih.gov/books/NBK470290/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC3986552/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC5703736/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC6911835/
  32. https://www.ncbi.nlm.nih.gov/books/NBK537352/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC9325038/
  34. https://panhematin.com/healthcare-professionals/dosing/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC6954746/
  36. https://www.panhematin.com/wp-content/themes/panhematin/assets/pdf/panhematin-dosing-and-administration-guide-mobile.pdf
  37. https://porphyriafoundation.org/for-patients/about-porphyria/treatment-options/panhematin-acute-porphyria/
  38. https://porphyriafoundation.org/for-healthcare-professionals/emergency-room-guidelines-for-acute-porphyrias/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC6358544/
  40. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=683
  41. https://www.mdpi.com/2227-9059/12/4/898
  42. https://e-century.us/files/ajtr/17/10/ajtr0164582.pdf
  43. https://www.nature.com/articles/cddis2014529
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC9137505/
  45. https://pubmed.ncbi.nlm.nih.gov/8405959/
  46. https://academic.oup.com/femsle/article/48/3/401/547419
  47. https://journals.asm.org/doi/10.1128/jb.00458-21
  48. https://www.sciencedirect.com/science/article/abs/pii/S014181302506180X
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC11403666/
  50. https://www.nature.com/articles/s41419-020-02950-8
  51. https://www.mdpi.com/1422-0067/20/1/39
  52. https://link.springer.com/article/10.1007/s11010-024-05119-5
  53. https://ashpublications.org/blood/article/144/Supplement%201/1108/529427/Quinine-Hemin-Compound-As-an-Anti-Inflammatory
  54. https://www.nature.com/articles/s42003-025-07983-3
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC4069941/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC5378770/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC11194834/
  58. https://www.uspharmacist.com/article/optimizing-the-use-of-hematologic-agents-a-case-based-approach-highlighting-the-use-of-ivig-hemin-and-azacitidine
  59. https://aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.21244
  60. https://www.ojp.gov/pdffiles1/pr/92422_part1.pdf
  61. https://pubs.rsc.org/en/content/articlepdf/1871/js/js8712400728
  62. https://www.danamatthiessen.com/wp-content/uploads/2024/10/Crystallizing-Techniques-final-unblinded.pdf
  63. https://www.nobelprize.org/uploads/2018/06/fischer-lecture-3.pdf
  64. https://www.nobelprize.org/prizes/chemistry/1930/fischer/biographical/
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC7319466/
  66. https://www.pnas.org/doi/10.1073/pnas.2108245119
  67. https://www.nature.com/articles/s41538-025-00453-4
  68. https://patents.google.com/patent/EP0236971B1/en
  69. https://www.tandfonline.com/doi/abs/10.1080/10408398.2011.605229
  70. https://patents.google.com/patent/US4761472A/en
  71. https://link.springer.com/article/10.1007/s12325-008-0094-y
  72. https://forensicreader.com/teichmann-test/
  73. https://www.ojp.gov/pdffiles1/nij/grants/244251.pdf
  74. https://www.ojp.gov/pdffiles1/pr/160880_unit_2.pdf
  75. https://forensicreader.com/takayama-test/
  76. https://www.researchgate.net/publication/342147787_Takayama_Test_as_a_Blood_Spot_Test_Tool_in_Blood_Samples_Exposed_to_Freshwater_Decomposition_Media
  77. https://www.sciencedirect.com/science/article/abs/pii/S0379073822002717
  78. https://crimereads.com/forensics-on-trial-americas-first-blood-test-expert/
  79. https://nij.ojp.gov/nij-hosted-online-training-courses/laboratory-orientation-and-testing-body-fluids-and-tissues/testing-body-fluids-tissues/blood/confirmatory-tests
  80. https://store.astm.org/products-services/standards-and-publications/standards/forensic-science-standards.html
  81. https://www.ncbi.nlm.nih.gov/books/NBK8458/
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC5125930/
  83. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-8-haemophilus-influenzae.html
  84. https://microbenotes.com/chocolate-agar/
  85. https://www.dalynn.com/dyn/ck_assets/files/tech/PC55.pdf
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC2045313/
  87. https://pubmed.ncbi.nlm.nih.gov/3493113/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC11753472/
  89. https://www.mpbio.com/pi/hemin-chloride-from-porcine
  90. https://www.himedialabs.com/us/m1039-brucella-agar-base-w-hemin-and-vitamin-k.html
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC6332241/
  92. https://ietresearch.onlinelibrary.wiley.com/doi/full/10.1049/mnl.2017.0654
  93. https://pubs.acs.org/doi/abs/10.1021/acs.estlett.7b00059
  94. https://www.nature.com/articles/s41467-022-30285-9
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC11873119/
  96. https://www.htfmarketintelligence.com/report/global-green-chemistry-market
Add your contribution
Related Hubs
User Avatar
No comments yet.